Navigation Links
BUSM professor authors book on how knowledge about genes and family history can save lives
Date:8/26/2011

lethal genetic disorders and even important treatment," said Milunsky. "By knowing your genes, you may save your life and the lives of those you love."

Milunsky's research accomplishments include leading the research team responsible for first locating the gene for X-linked lymphoproliferative disease and cloning the PAX 3 gene for Waardenburg syndrome. As principal investigator, he also led a team that was the first to demonstrate that 70 percent of spina bifida cases could be avoided by folic acid supplementation taken 3 months prior to pregnancy and 3 months after conception.

Milunsky joined the Boston University community in 1982 when he was named Founding Director of the Center for Human Genetics and appointed Professor of Pediatrics and Obstetrics and Gynecology, both at BUSM. He became a Professor of Pathology in 1985, and in 1991 became the first Endowed Chair in Human Genetics at BUSM, which will be named for him upon his retirement. He has been honored by election as a Fellow of the Royal College of Physicians of England and as a member of the Society for Pediatric Research and the American Pediatrics Society. He is also a Founding Fellow of the American College of Medical Genetics.

In addition to his academic and research successes, Milunsky is the author or co-author of more than 400 scientific communications and author, editor or co-editor of 24 books.

Your Genes, Your Health: A Critical Family Guide That Could Save Your Life, was published by Oxford University Press and is available now to the public.


'/>"/>

Contact: Jenny Eriksen Leary
jenny.eriksen@bmc.org
617-638-6841
Boston University Medical Center
Source:Eurekalert

Page: 1 2

Related biology news :

1. BUSM professor awarded $13.3 million to study potential treatments to prevent STDs
2. FASEB MARC program announces the travel award recipients for the 2011 Leadership Development and Grant Writing Seminar for graduate students, postdoctoral fellows and new assistant professors
3. MSU professor launches new field of water research, nets $2.2 million NSF grant
4. Trauma drama: K-State professor researches drama queen of immune system
5. Acclaimed chemistry professor wins 2 major awards
6. University of Houston professor co-authors PNAS paper on how bacteria move
7. BUSM professor selected as American Heart Association Distinguished Scientist
8. CWRU law professor eyes prize-based incentives to generate climate innovation
9. Sugar-based chemicals book chapter by NJIT professor takes ACS kudos
10. University of Texas at Austin professor receives Donald L. Katz Award
11. CSHL professor Rob Martienssen receives prestigious appointment as HHMI-GBMF investigator
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... September 17, 2014 Researchers at UTSouthwestern Medical ... the circulating protein apolipoprotein E, called apoE3, helps repair ... called apoE4, do not get the benefit of this ... , "We believe that we have identified one mechanism ... why a genetic variant, apoE4, is detrimental," said ...
(Date:9/17/2014)... 1960s. The typical development phases of trees and stands ... as much as 70 percent. This was the outcome ... Universitt Mnchen based on long-term data from experimental forest ... findings were published recently in Nature Communications . ... topic, with the very survival of large forest ecosystems ...
(Date:9/17/2014)... including MRSA and MSSA could be curbed by ... the scaly surface of shark skin, according to ... Antimicrobial Resistance and Infection Control . , The ... spread of human disease bacteria through touching, sneezes ... arrangement of ridges formulated to resemble shark skin. ...
Breaking Biology News(10 mins):Protein variant may boost cardiovascular risk by hindering blood vessel repair 2Global change: Trees continue to grow at a faster rate 2Global change: Trees continue to grow at a faster rate 3Sharks' skin has teeth in the fight against hospital superbugs 2
... real cost of Herceptin is borne by other patients whose ... doctors in this week’s BMJ. , New guidance from the ... (Herceptin) in early breast cancer, but it provides no extra ... to release this extra money. This leaves medical staff with ...
... larvae, warmed in a toasty lab chamber, are giving Cornell ... see how genes are expressed in living tissue. , Using ... Watt W. Webb, researchers have for the first time been ... activate their genes to synthesize key proteins in fruit fly ...
... protein converts chemical energy to mechanical force, thus powering ... structural model by University of North Carolina at Chapel ... a scientific mystery: how the protein dynein fuels itself ... include mitosis, or cell division into identical cells. ...
Cached Biology News:Other patients bear the real cost of Herceptin 2Researchers use multiphoton microscopy to watch chromosomes in action 2Researchers use multiphoton microscopy to watch chromosomes in action 3UNC scientists solve mystery of how largest cellular motor protein powers movement 2
(Date:9/17/2014)... VIENNA , Sept. 17, 2014 ... compelling, quantitative data from a study of the cost ... at the 50 th Annual Meeting of the ... a poster session today, Christian Frois , Ph.D., ... in a series of planned Intarcia-sponsored, retrospective studies to ...
(Date:9/17/2014)... 2014 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD) (OTCQX: ... proprietary technologies and products for advanced microarray diagnostics, today ... trading in the United States ... commence on September 17, 2014 on the OTCQX under ... on the TSX Venture Exchange under its existing symbol ...
(Date:9/17/2014)... 17 de septiembre de 2014  Cryoport, ... proveedor mundial de soluciones logísticas avanzadas criogénicas ... la vida, anunció hoy la contratación de ... con sede en Rótterdam, Países Bajos, para ... Europa en rápido crecimiento. Según los términos ...
(Date:9/17/2014)... Scotland , September 17, 2014 /PRNewswire/ ... new mode of action from a truly ... decade  MGB Biopharma, a biopharmaceutical ... anti-infectives, announces today that it has secured ... its lead antibacterial, MGB-BP-3, against a range ...
Breaking Biology Technology:Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 2Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 4Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 5SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 2SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 3Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 2Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 3Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 4Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 2MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 6MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 7
... , , , ... NGSX ), a biopharmaceutical company focused on developing and commercializing ... Goodwin to its Board of Directors as a director and Audit ... President and CEO of Keren Pharmaceutical, a company focused on exploiting ...
... , , , WALTHAM, ... leading research and advisory firms for pharmaceutical and healthcare issues, ... most notably Novartis,s Diovan -- the hypertension drug market will ... the market will decrease by 1.4 percent annually and thereafter ...
... , GAITHERSBURG, Md., Aug. 25 GenVec, Inc. (Nasdaq: ... Phase 2 Small Business Innovation and Research (SBIR) grant from the ... Institutes of Health (NIH) to support the development of GenVec,s vector ... http://www.newscom.com/cgi-bin/prnh/ 2 0081205/DC50112LOGO ) , , ...
Cached Biology Technology:NeurogesX Appoints New Board Director and Audit Committee Chairman 2NeurogesX Appoints New Board Director and Audit Committee Chairman 3NeurogesX Appoints New Board Director and Audit Committee Chairman 4NeurogesX Appoints New Board Director and Audit Committee Chairman 5Hypertension Drug Market Will Experience Only Modest Annual Decline Through 2018, Despite Generic Erosion Of Many Branded Agents 2GenVec Receives an Approximately $2.5 Million Grant to Support Novel Cell Line Development 2